Pancreatic Cancer Therapeutics and Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 4.56 Billion |
| Market Size (2029) | USD 6.55 Billion |
| CAGR (2024 - 2029) | 7.52 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pancreatic Cancer Therapeutics and Diagnostics Market Analysis
The Pancreatic Cancer Therapeutics And Diagnostics Market size is estimated at USD 4.56 billion in 2024, and is expected to reach USD 6.55 billion by 2029, growing at a CAGR of 7.52% during the forecast period (2024-2029).
Pancreatic cancer therapeutics and diagnostics involve medical procedures for diagnosing pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, drug development, and pancreatic cancer diagnostic technology play a major part in pancreatic cancer market growth. With the increase in research and development initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period. For instance, according to the Australian Pancreatic Cancer Foundation Statistics published in 2023, pancreatic cancer was diagnosed in 4,506 patients in 2023. Pancreatic cancer was the eighth most prevalent disease diagnosed in Australia in 2023. Thus, the growing burden of pancreatic cancer is expected to boost the demand for effective diagnosis and treatment, which is likely to propel the growth of the pancreatic cancer treatment market during the forecast period. Rising research and development activities for pancreatic cancer medication, as well as a large product pipeline, may increase product approval by regulatory authorities, increasing the accessibility and availability of a greater number of drugs to treat pancreatic cancer and contributing to pancreatic cancer treatment drugs market growth. For instance, in February 2023, updated results of the fully enrolled cohort of the phase 2 QUILT 88 study (NCT03563144) showed a doubling of survival in third-line patients with metastatic pancreatic cancer when treated with the novel combination immunotherapy protocol of low-dose chemoradiation, N-803, and PDL1 t-haNK therapy. These promising results may have significant implications for the metastatic pancreatic cancer market. Also, in April 2023, Cantargia reported new findings from the phase I/IIa clinical trial CANFOUR, designed to evaluate nadunolimab in combination with chemotherapy for treating pancreatic cancer. Patients with high tumor levels of IL1RAP benefit from nadunolimab treatment. Hence, promising clinical trial studies lead to product approvals, which are expected to drive the market during the forecast period. Thus, all aforementioned factors, such as the increasing prevalence of pancreatic cancer and rising research and development activities, are expected to boost the market growth during the forecast period. However, the high cost of diagnosis and treatment may restrain the growth of the pancreatic cancer therapeutics and diagnostics market during the forecast period.
Pancreatic Cancer Therapeutics and Diagnostics Market Trends
The Chemotherapy Segment is Estimated to Hold Significant Share in the Market During the Forecast Period
Chemotherapy is one of the main cancer treatments that kills pancreatic cancer cells by preventing them from growing and dividing. These pancreatic cancer chemotherapy drugs are systemic treatments; they travel through the bloodstream and damage cancer cells throughout the body. Unfortunately, chemotherapy can damage some healthy cells and cause major side effects. Chemotherapy may shrink and prevent the growth of pancreatic tumors. According to the American Cancer Society, the chemotherapy drugs used to treat pancreatic cancer include gemcitabine (Gemzar), 5-fluorouracil (5-FU), irinotecan (Camptosar), oxaliplatin (Eloxatin), albumin-bound paclitaxel (Abraxane), capecitabine (Xeloda), cisplatin, paclitaxel (Taxol), docetaxel (Taxotere), and irinotecan liposome (Onivyde). Factors such as the growing burden of pancreatic cancer, advancements in chemotherapy drug developments, and increasing research studies in the chemotherapy field are contributing to the growth of the segment. The major players are engaging in research and development strategies to innovate better treatment options for chemotherapy. For instance, according to the article published by the University of Rochester in November 2023, the university-developed experimental drug NP137 is considered for clinical trials on pancreatic cancer at Wilmot Cancer Institute. In January 2022, ZaiLab Limited reported the successful treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 trial evaluating the efficacy of tumor-targeting fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer. Hence, the increasing research and development activities to innovate new chemotherapies are expected to drive the pancreatic cancer therapy market during the forecast period. Thus, the segment is expected to witness significant growth during the forecast period due to the surging demand for effective treatment options for pancreatic cancers, particularly in the pancreatic adenocarcinoma treatment market and pancreatic oncology.
North America Holds Significant Share in the Market and Expected to Grow During the Forecast Period
North America is expected to retain its significant market share due to the rising incidence of pancreatic cancer, supportive reimbursement policies, and high healthcare spending. According to the May 2023 Statistics by the Canadian Cancer Society, in 2023, 7,200 Canadians were diagnosed with pancreatic cancer, with 4,000 males and 3,200 women affected. The rising pancreatic cancer cases may drive the demand for pancreatic cancer diagnostics market and treatment in the region. Moreover, the US FDA is taking steps to enhance the growth of the pancreatic cancer therapeutics and diagnostics market by approving drugs in the clinical phase, thereby accelerating clinical developments. For instance, in September 2022, the FDA granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer. Also, the increasing focus on research studies and clinical trials in the region and collaboration among the societies and foundations for funding are driving the market's growth. For instance, in March 2022, the Pancreatic Cancer Convergence Dream Team was funded by the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up to Cancer (SU2C), for a new clinical trial that studied pancreatic cancer tumor traits to uncover better treatment options. Such funding by private and government organizations for the development of pancreatic cancer therapies is expected to boost the pancreatic cancer therapy market in North America. Companies and research organizations are investing in R&D and adopting various strategies, such as collaboration and partnership. For instance, in January 2022, Seqster entered a multi-year partnership with The National Pancreas Foundation, a non-profit organization that provides resources for those suffering from pancreatitis and pancreatic cancer, to create the country's largest and most inclusive pancreatic disease patient registry. The registry uses Seqster technology to connect to any electronic health record (EHR), genomic DNA test, and wearable or remote monitoring device, providing patients with a complete longitudinal health record in real time. Thus, all the factors above, such as the rising incidence of pancreatic cancer and supportive reimbursement policies by the government, are expected to boost the growth of the pancreatic cancer diagnosis market in North America during the forecast period.
Pancreatic Cancer Therapeutics and Diagnostics Industry Overview
The pancreatic cancer therapeutics market is highly competitive, with many key players dominating the market. The presence of major market players like Novartis AG, Pfizer Inc., Immunovia AB, AstraZeneca PLC, Myriad Genetics Inc., and Viatris Inc. is intensifying the competition. The market players are adopting strategies, such as increasing R&D investments in pancreatic cancer drugs, mergers, acquisitions, and product innovations, to sustain the increasing competition in the market.
Pancreatic Cancer Therapeutics and Diagnostics Market Leaders
-
Myriad Genetics, Inc.
-
Pfizer, Inc
-
Novartis AG
-
AstraZeneca plc
-
Immunovia AB
*Disclaimer: Major Players sorted in no particular order
Pancreatic Cancer Therapeutics and Diagnostics Market News
- February 2024: The United States Food and Drug Administration approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. The approval was based on NAPOLI 3 (NCT04083235), a randomized study that assessed the drug's efficacy among metastatic pancreatic adenocarcinoma patients.
- January 2024: The United States Food and Drug Administration cleared an investigational new drug (IND) application for ACT-IOP-003, an implantable iontophoretic product, as a potential treatment for patients with pancreatic cancer, and a phase 1b trial of the agent plans to start mid-2024.
Pancreatic Cancer Therapeutics And Diagnostics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
4.2.2 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology
4.3 Market Restraints
4.3.1 High Costs Associated with Diagnosis and Treatments
4.3.2 Stringent Regularity Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD)
5.1 By Type
5.1.1 Treatment
5.1.1.1 Targeted Therapies
5.1.1.2 Chemotherapy
5.1.1.3 Surgery
5.1.1.4 Other Treatments
5.1.2 Diagnostics
5.1.2.1 Imaging
5.1.2.2 Biopsy
5.1.2.3 Endoscopic Ultrasound
5.1.2.4 Other Diagnostics
5.2 By End User
5.2.1 Hospitals and Clinics
5.2.2 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Myriad Genetics Inc.
6.1.2 Novartis AG
6.1.3 ClearNote Health
6.1.4 AstraZeneca PLC
6.1.5 Prestige Biopharma
6.1.6 Boston Scientific Corporation
6.1.7 FUJIFILM Holdings Corporation
6.1.8 Canon Inc. (Canon Medical Systems Corporation)
6.1.9 Immunovia AB
6.1.10 Apexigen Inc.
6.1.11 Pfizer Inc
6.1.12 F Hoffmann-La Roche AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Pancreatic Cancer Therapeutics and Diagnostics Industry Segmentation
As per the scope, pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine based on the cells affected by cancer. The pancreatic cancer therapeutics and diagnostics market is segmented by type, end user, and geography. By type, the market is segmented into treatment (targeted therapies, chemotherapy, surgery, and other treatments) and diagnostics (imaging, biopsy, endoscopic ultrasound, and other diagnostics). By end user, the market is segmented into hospitals, clinics, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Type | ||||||
| ||||||
|
| By End User | |
| Hospitals and Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pancreatic Cancer Therapeutics And Diagnostics Market Research Faqs
How big is the Pancreatic Cancer Therapeutics And Diagnostics Market?
The Pancreatic Cancer Therapeutics And Diagnostics Market size is expected to reach USD 4.56 billion in 2024 and grow at a CAGR of 7.52% to reach USD 6.55 billion by 2029.
What is the current Pancreatic Cancer Therapeutics And Diagnostics Market size?
In 2024, the Pancreatic Cancer Therapeutics And Diagnostics Market size is expected to reach USD 4.56 billion.
Who are the key players in Pancreatic Cancer Therapeutics And Diagnostics Market?
Myriad Genetics, Inc., Pfizer, Inc, Novartis AG, AstraZeneca plc and Immunovia AB are the major companies operating in the Pancreatic Cancer Therapeutics And Diagnostics Market.
Which is the fastest growing region in Pancreatic Cancer Therapeutics And Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pancreatic Cancer Therapeutics And Diagnostics Market?
In 2024, the North America accounts for the largest market share in Pancreatic Cancer Therapeutics And Diagnostics Market.
What years does this Pancreatic Cancer Therapeutics And Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Pancreatic Cancer Therapeutics And Diagnostics Market size was estimated at USD 4.22 billion. The report covers the Pancreatic Cancer Therapeutics And Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pancreatic Cancer Therapeutics And Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pancreatic Cancer Therapeutics And Diagnostics Industry Report
Statistics for the 2024 Pancreatic Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pancreatic Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Pancreatic Cancer Therapeutics And Diagnostics Market Report Snapshots
